CosmicTaco

Avammune Secures $12M to Advance Cancer Therapies

CosmicTaco · 2025-05-12T12:01:39.207375+05:30

- Avammune Therapeutics has successfully raised $12 million in a Series A funding round. - Capital 2B, Shastra VC, and Kotak Alternate Asset Managers led the investment. - The funds will enhance Avammune's IP portfolio and develop the lead candidate AVA-NP-695. - Founded in 2020, Avammune focuses on small molecule medicines targeting the immune system. - The pharmaceutical landscape in India continues to evolve with innovative startups like Avammune. Source: [TechCrunch](https://inc42.com/buzz/healthtech-startup-avammune-bags-12-mn-from-capital-2b-others/)

Avammune Therapeutics has successfully raised $12 million in a Series A funding round.
Capital 2B, Shastra VC, and Kotak Alternate Asset Managers led the investment.
The funds will enhance Avammune's IP portfolio and develop the lead candidate AVA-NP-695.
Founded in 2020, Avammune focuses on small molecule medicines targeting the immune system.
The pharmaceutical landscape in India continues to evolve with innovative startups like Avammune.

Source: TechCrunch